VYANT BIO INC (VYNT) Stock Price, Forecast & Analysis
USA - NASDAQ:VYNT - US92942V2088 - Common Stock
VYNT Key Statistics, Chart & Performance
The current stock price of VYNT is 0.26 USD. In the past month the price decreased by -52.13%. In the past year, price decreased by -92.17%.
VYNT Latest News, Press Relases and Analysis
VYNT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 382.94B | ||
| AMGN | AMGEN INC | 14.63 | 172.20B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.02 | 106.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.31 | 68.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 852.08 | 56.96B | ||
| ARGX | ARGENX SE - ADR | 62.07 | 51.25B | ||
| INSM | INSMED INC | N/A | 39.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.19 | 35.30B | ||
| NTRA | NATERA INC | N/A | 27.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.86B | ||
| BIIB | BIOGEN INC | 9.17 | 22.49B |
Related stock screener links
About VYNT
Company Profile
Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The company is headquartered in Cherry Hill, New Jersey and currently employs 8 full-time employees. The company went IPO on 2013-04-10. The firm is engaged in combining sophisticated data science capabilities with highly functional human cell derived disease models. Its central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. The Company’s platform is designed to elucidate disease pathophysiology; formulate key therapeutic hypotheses; identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection, and guide clinical trial patient selection and trial design. The Company’s programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders, including Rett Syndrome (Rett), CDKL5 Deficiency Disorders (CDD) and familial Parkinson’s Disease (PD).
Company Info
VYANT BIO INC
2 Executive Campus, 2370 State Route 70, Suite 310
Cherry Hill NEW JERSEY 07070 US
CEO: John A. Roberts
Employees: 8
Phone: 12015289200.0
VYANT BIO INC / VYNT FAQ
What does VYANT BIO INC do?
Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The company is headquartered in Cherry Hill, New Jersey and currently employs 8 full-time employees. The company went IPO on 2013-04-10. The firm is engaged in combining sophisticated data science capabilities with highly functional human cell derived disease models. Its central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. The Company’s platform is designed to elucidate disease pathophysiology; formulate key therapeutic hypotheses; identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection, and guide clinical trial patient selection and trial design. The Company’s programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders, including Rett Syndrome (Rett), CDKL5 Deficiency Disorders (CDD) and familial Parkinson’s Disease (PD).
Can you provide the latest stock price for VYANT BIO INC?
The current stock price of VYNT is 0.26 USD. The price decreased by -23.51% in the last trading session.
Does VYANT BIO INC pay dividends?
VYNT does not pay a dividend.
What is the ChartMill rating of VYANT BIO INC stock?
VYNT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting VYNT stock to perform?
7 analysts have analysed VYNT and the average price target is 5.1 USD. This implies a price increase of 1861.54% is expected in the next year compared to the current price of 0.26.
What is the employee count for VYNT stock?
VYANT BIO INC (VYNT) currently has 8 employees.
Can you provide the market cap for VYANT BIO INC?
VYANT BIO INC (VYNT) has a market capitalization of 1.63M USD. This makes VYNT a Nano Cap stock.
VYNT Technical Analysis
VYNT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VYNT. VYNT has a bad profitability rating. Also its financial health evaluation is rather negative.
VYNT Financial Highlights
Over the last trailing twelve months VYNT reported a non-GAAP Earnings per Share(EPS) of -3.91. The EPS decreased by -101.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.03 |
VYNT Forecast & Estimates
7 analysts have analysed VYNT and the average price target is 5.1 USD. This implies a price increase of 1861.54% is expected in the next year compared to the current price of 0.26.
For the next year, analysts expect an EPS growth of 37.93% and a revenue growth -100% for VYNT